Biochemical evolution of serum IgG-Kappa monoclonal component during the first line with VRD (x1), DARA-VRD (x4), and the second line with ISA-KD (x4).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10805998 | PMC |
| http://dx.doi.org/10.1002/ccr3.8449 | DOI Listing |
Publication Analysis
Top Keywords
isatuximab-carfilzomib-dexamethasone failing
4
failing quadruplet
4
quadruplet daratumumab-bortezomib-lenalidomide-dexamethasone
4
daratumumab-bortezomib-lenalidomide-dexamethasone dara-vrd
4
dara-vrd striking
4
striking response
4
response washout
4
washout newly
4
newly diagnosed
4
diagnosed multiple
4
Similar Publications
Isatuximab-carfilzomib-dexamethasone immediately after failing of the quadruplet Daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRD): Striking response with no washout in a newly diagnosed multiple myeloma.
Clin Case Rep
January 2024
Hematology Department University Hospital Principe de Asturias Alcala de Henares Spain.
Biochemical evolution of serum IgG-Kappa monoclonal component during the first line with VRD (x1), DARA-VRD (x4), and the second line with ISA-KD (x4).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!